AKT1 and cancer: The “drug–ingredients–targets–pathways–disease” network analysis highlighted highly enriched targets, including AKT1, TP53, and TNF, and pathways, such as pathways in cancer (hsa05200), lipid metabolism and atherosclerosis (hsa05417), and the PI3K-Akt signaling pathway (hsa04151) (Figure 6).